Modulation of multidrug resistance (MDR) in hematological malignancies

Annals of Oncology

Volumn 10, Issue SUPPL. 6, 1999, Pages

  Covelli, Alfredo ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Clinical trials; Hematological malignancies; Leukemia; Multidrug resistance; P glycoprotein; Valspodar

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN; IDARUBICIN; MITHRAMYCIN; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; TENIPOSIDE; TRIMETREXATE; VALSPODAR; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; CONFERENCE PAPER; CROSS RESISTANCE; GENE OVEREXPRESSION; LEUKEMIA; LYMPHOMA; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0033378748     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_6.S53     Document Type: Conference Paper

References (87)

1. Goldie JH, Coldman AJ. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 1983; 67: 923-30.
2. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese Hamster cells in vitro: cross-resistance, radioautographic and cytogenetic studies. Cancer Res 1970; 30: 1174-84.
3. Fojo AT, Whang-Peng J, Gottesmann MM. Amplification of DNA sequences in human multidrug-resistance KB carcinoma cells. Proc Natl Acad Sci USA 1985; 82: 7661-5.
4. Gros P, Neriah BY, Croop JM et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986; 323: 728-31.
5. Goldstein LJ, Galski H, Fojo A et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 2: 116-24.
6. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 1976; 455: 152-62.
7. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983; 221: 1285-8.
8. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 385-427.
9. Cole SP. Bhradwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
10. Muller M, Meijer C, Zaman GJ et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994; 91:13033-7.
11. Eijdems EW, Zaman GJ, de Haas M et al. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells. Br J Cancer 1995; 72: 298-306.
12. Scheffer GL, Wijngaard PL, Flens MJ et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995; 1: 578-82.
13. List AF, Spier CS, Grogan TM et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464-9.
14. Ross DD, Doyle LA, Schiffer CA et al. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia 1996; 10: 48-55.
15. Moscow JA, Fairchild CR, Madden MJ et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989; 49: 1422-8.
16. Sandor V, Wyndham W, Fojo T et al. The role of MDR-1 in refractory lymphoma. Leukemia & Lymphoma, 1997; 28: 23-31.
17. Kang Y, Zhan Z, Regis J et al. Expression of mdr-1 in refractory lymphoma. Quantitation by polymerase chain reaction and validation of the assay. Blood, 1995; 86:1515-24.
18. Pileri SA, Sabattini E, Falini B et al. Immunohistochemical detection of the multidrug transporter protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991; 19: 131-40.
19. Dan S, Esumi M, Sawada U et al. Expression of a multidrug-resistance gene in human malignant lymphomas and related disorders. Leukemia Res 1991; 15: 1139-43.
20. Cheng AL, Su IJ, Chen YC et al. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993; 11: 109-15.
21. Niehans GA, Jaszcz W, Brunetto V et al. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 1992; 52: 3768-75.
22. Miller TP, Grogan TM, Dalton WS, et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol, 1991; 9:17-24.
23. Yuen Ar, Sikic BI. Multidrug resistance in lymphomas. J Clin Onc 1994; 12: 2453-9.
24. Cornelissen J, Sonneveld P, Schoester M et al. MDR1 expression and response to vincristine, doxorubicin and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol 1994; 12: 115-9.
25. Grogan TM, Spier CM, Salmon SE et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490-5.
26. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913-17.
27. Lynsenmeyer ME, Jefferson S, Wolf M et al. Levels of expression of the mdr1 gene and glutathione-S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer 1992; 65: 471-5.
28. Lokhorts HM, Izquierdo MAI, Raaijmakers MGP et al. Lung-resistance protein expression is a negative predictive factor for response to alkylating chemotherapy and survival in multiple myeloma. Blood 1996; (suppl) 88:640a.
29. Pastan P, Schouten H. Multidrug resistance mediated by P-glycoprotein in haematological malignancies. Neth J Med 1993; 42: 218-31.
30. Licht T, Pastan I, Gottesman M et al. P-glycoprotein mediated multidrug resistance in normal and neoplastic haemopoietic cells. Annals Hematol 1994; 69:159-71.
31. Nooter K, Sonneveld P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leuk Res 1994; 18: 233-43.
32. Marie JP. P-glycoprotein in adult hematological malignancies. Hematol Oncol Clin N Am 1995; 9: 239-50.
33. Zhou D, Marie JP, Suberville A et al. Relevance of MDR-1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6:879-85.
34. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-9.
35. Willman C. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Seminars in Hematology, 1997; 34 (Suppl 5): 25-53.
36. Miyachi H, Takemura Y, Yonekura S et al. MDR1 (multidrug resistance) gene expression in adult acute leukemia: correlations with blast phenotype. Int J Hematol 1993; 57: 31-7.
37. Paietta E, Anderson J, Racevskis J et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994; 8: 968-73.
38. Drach D, Zhao S, Drach J. Low incidence of MDR1 expression in acute promyelocytic leukemia. Br J Hematol 1995; 90: 369-74.
39. Del Poeta G, Venditti A, Aronica G et al. P-glycoprotein expression in de novo acute myeloid leukemia. Leukemia and Lymphoma 1997; 27: 257-74.
40. Holmes J, West R. The effect of MDR1 gene expression on outcome in acute myeloid leukaemia. Br J Cancer 1994; 69: 382-4.
41. Te Boekhorst P, de Leeuww K, Schoester M et al. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ myeloid leukemia cells. Blood 1993; 79: 3157-2.
42. Campos L, Guyotat D, Archimbaud E et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-6.
43. Lamy T, Goasguen D, Mordeletb E et al. P-glycoprotein (P-170) and CD34 expression in adult acute leukemia (AML). Leukemia 1994; 8: 1879-83.
44. Wood P, Burgess R, McGregor A et al. P-glycoprotein expression on acute myeloid leukaemia blasts cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol. 1994; 87:509-14.
45. Kuwazuru Y, Yoshimura A, Hanada S et al. Expression of the multidrug transporter P-glycoprotein in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868-73.
46. Marie JP, Zittoun R, Sikic B. Multidrug resistance gene (mdr) expression in adult acute leukemias: correlation with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586-92.
47. Pirker R, Wallner J, Geissler K et al. MDR-1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708-12.
48. Michieli M, Damiani D, Geromin A et al. Overexpression of multidrug resistance-associated p-170 glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 1992; 48: 87-92.
49. Tirikainen M, Elonen E, Ruutu T, et al. Clinical significance of P-glycoprotein expression in acute leukemia as analysed by immunocytochemistry. Eur J Haematol 1993; 50: 279-85.
50. Zöchbauer S, Gsur A, Brunner R, et al. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994; 8: 975-7.
51. Basara N, Radosevic-Radojkovic N, Colovic M et al. In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult myeloid leukemia: correlation with induction treatment outcome. Eur J Haematol 1995; 55: 83-7.
52. Zhou D, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995; 9:1661-6.
53. Filipits M, Pohl G, Stranzl T et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 5:1508-13.
54. Filipits M, Suchomel RW, Zöchbauer S et al. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res 1997; 3: 1419-25.
55. Lum BI, Fisher GA, Brophy NA et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 1993; 72: 3502-14.
56. Ford J and Hait W. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1993; 42: 156-99.
57. Fisher GA, Lum BL, Hausdorff J et al. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996; 32A: 1082-8.
58. Fisher GA and Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995; 9: 363-82.
59. Yahanda AM, Adler KM, Fisher GA, et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol, 1992; 10:1624-34.
60. Twentyman PR. Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins. Br J Cancer 1988; 57: 254-8.
61. Boesch D, Muller K, Poutier-Manzanedo A et al. Restoration of daunomycin retention in multidrug resistant P388 cells by submicromolar concentrations of SDZ PSC 833. Exp Cell Res 1991; 196: 26-32.
62. Twentyman PR and Blechen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 1991; 27: 639-42.
63. Archinal Mattheis A, Rzepka RW, Watanabe T et al. Analysis of the interactions of SDZ PSC 833 ([3'keto-BMTI]-Val2]cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 1995; 7: 603-10.
64. Foxwell BM, Mackie A, Ling V et al. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 1989; 36: 534-46.
65. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol 1992; 43: 109-17.
66. Sonneveld P, Marie JP, Huisman C et al. Reversal of multidrug resistance by PSC 833 combined with VAD in refractory multiple myeloma: a phase 1 study. Leukemia 1996; 10: 1741-50.
67. Boote DJ, Dennis IF, Twentyman PR et al. Phase 1 study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996; 14: 610-8.
68. Sonneveld P, Lowenberg B, Vossebled P et al. Dose finding study of PSC 833, a novel MDR reversing agent, with daunorubicin and Ara-C in untreated elderly patients with acute myeloid leukemia (AML). Blood, 1997; 90(Suppl 1) Abstract 2517.
69. Advani R, Saba H, Tallman M et al. Treatment of poor prognosis AML patients with PSC 833 plus mitoxantrone, etoposide and cytarabine (PSC-MEC). Blood 1997; 90 (Suppl 1) Abstract 2260.
70. Visani G, Milligan D, Leoni F et al. A phase 1 dose-finding study of PSC 833, a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine (PSC-MEC) in poor prognosis acute leukemia (AML). Blood 1997; 90 (Suppl 1) Abstract 2518.
71. Sikic BI. Pharmacologic approaches to reversing multidrug resistance. Seminars in Hematol 1997; 34 (Suppl 5):40-7.
72. Miller TP, Grogan TM, Dalton WS et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical resistance with chemotherapy plus high dose verapamil. J Clin Onc 1991; 9:17-24.
73. Wilson WH, Bates SE, Fojo A et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Onc 1995; 13: 1995-2004.
74. Sarris AH, Younes A, McLaughlin P et al. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Onc 1996; 14: 233-9.
75. Yuen A, Breslin S, Sikic BI et al. A phase I/II trial of ONCEP chemotherapy with the multidrug resistance modulator PSC 833 in patients with recurrent or refractory non-Hodgkin's lymphoma. American Society of Clinical Oncology, 34th Annual Meeting, 1998; Abstract 48
76. Salmon SE, Dalton WS, Grogan TM et al. Multidrug resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44-50.
77. Dalton WS, Crowley JJ, Salmon SS et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 1995; 75: 815-20.
78. Sonneveld P, Dune BGM, Lokhorts HM et al. Modulation of multidrug resistant multiple myeloma by cyclosporin. Lancet 1992; 340: 255-59.
79. Sonneveld P, Marie JP, Huisman C et al. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 1996; 10:1741-50.
80. Solary E, Witz B, Caillot D et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996; 88: 1198 1205.
81. Sonneveld P, Nooter K. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Brit J Haem 1990; 75: 208-11.
82. List AF, Spier C, Greer J et al. Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-60.
83. List A, Karanes C, Dorr R et al. Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC 833: results of a phase I/II multicenter study. Blood 1996; 88 (Suppl 1) Abstract 1156.
84. Kornblau SM, Estey E, Madden T et al. Phase I study of mitoxantrone plus etoposide with multidrug resistance blockade by SDZ PSC 833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997; 15: 1796-1802.
85. Sonneveld P, Lowenberg B, Vossebled P et al. Dose finding study of PSC 833, a novel MDR reversing agent, with daunorubicin and Ara-C in untreated elderly patients with acute myeloid leukemia (AML). Blood 1997; 90(Suppl 1) Abstract 2517.
86. Lee E, George S, Caligiuri M et al. A phase I study of induction chemotherapy for older patients (pts) with acute myeloid leukemia (AML) using Ara-C (A), daunorubicin (D) and etoposide (E) with and without the MDR modulator PSC 833 (P): Cancer and Leukemia Group B (CALGB) study 9420. Blood 1997; 90 (Suppl 1) Abstract 2256.
87. Beketic-Oreskovic L, Duran GE, Chen G et al. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdrI gene activation by the cyclosporin PSC K33. J Natl Cancer Inst 1995; 87:1593-1602.